RA
RAPP.US Rapport Therapeutics, Inc. Common Stock
- Market cap
- USD 1.41B
- P/E
- -
- P/B
- 3.76x
- ROE
- -39.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RAPP.US undervalued?
Graham numberThe Graham number of Rapport Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rapport Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Rapport Therapeutics, Inc. Common Stock yet.
Rapport Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other C…
Full company profileRapport Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rapport Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 26.7M |
| Gross Profit | -15.0K | -112K | -839K | -1.02M | - |
| Operating Income | -10.4M | -36.2M | -83.1M | -125M | -172M |
| EBITDA | -10.4M | -34.7M | -82.2M | -124M | -161M |
| Net Income | -10.7M | -34.8M | -78.3M | -111M | -156M |
| EPS | -0.29 | -0.95 | -2.14 | -2.86 | -3.26 |
| Balance Sheet | |||||
| Total Assets | 31.6M | 155M | 315M | 512M | 419M |
| Total Liabilities | 12.1M | 181M | 9.51M | 27.8M | 27.4M |
| Shareholders' Equity | 19.5M | -25.6M | 305M | 485M | 391M |
| Cash & Short-term Investments | 31.2M | 147M | 305M | 491M | 395M |
| Total Debt | 10.4M | 2.15M | 1.48M | 11.5M | 9.39M |
| Cash Flow | |||||
| Operating Cash Flow | -3.24M | -27.2M | -64.8M | -87.5M | -128M |
| Capital Expenditure | 284K | 1.64M | 2.41M | 616K | 219K |
| Free Cash Flow | -3.53M | -28.8M | -67.2M | -88.1M | -128M |
| Ratios | |||||
| ROE | -54.6% | - | -25.6% | -23.0% | -39.8% |
| ROA | -33.7% | -22.4% | -24.9% | -21.8% | -37.2% |
| Net Profit Margin | - | - | - | - | -583.5% |
| Debt to Equity | 0.53x | - | 0.00x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rapport Therapeutics, Inc. Common Stock dividends
Rapport Therapeutics, Inc. Common Stock has not paid dividends in the last 4 fiscal years.
Who owns Rapport Therapeutics, Inc. Common Stock
- Insiders 3.17%
- Institutions 86.38%
- Public & others 10.45%
- Shares outstanding 59.3M
- Free float 44.9M
Top funds holding RAPP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 3.12M | 5.40% | -7.65% | Sep 2026 |
| Fidelity Growth Company Fund | 2.26M | 3.90% | +0.34% | Aug 2026 |
| Polar Capital Biotech S Inc | 1.52M | 2.63% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.14M | 1.98% | +15.85% | Sep 2026 |
| iShares Russell 2000 ETF | 772K | 1.34% | 0.00% | Oct 2026 |
| Fidelity Growth Company K6 | 692K | 1.20% | +0.35% | Aug 2026 |
| Fidelity Series Growth Company | 594K | 1.03% | +0.30% | Aug 2026 |
| T. Rowe Price Health Sciences | 461K | 0.80% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 428K | 0.74% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 335K | 0.58% | 0.00% | Aug 2026 |
| Candriam Eqs L Biotech C USD Cap | 329K | 0.57% | +76.84% | Apr 2026 |
| Artisan International Small-Mid Investor | 308K | 0.53% | 0.00% | Sep 2026 |
| AB Small Cap Growth A | 275K | 0.47% | -2.51% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 269K | 0.46% | -0.38% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 230K | 0.40% | +24.03% | Oct 2026 |
| iShares Biotechnology ETF | 224K | 0.39% | -0.19% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 196K | 0.34% | +2.88% | Oct 2026 |
| UBS (Lux) EF Biotech (USD) P-acc | 181K | 0.31% | -2.12% | Jul 2026 |
| Vanguard Russell 2000 ETF | 178K | 0.31% | +1.13% | Sep 2026 |
| Fidelity Extended Market Index | 163K | 0.28% | +15.59% | Sep 2026 |
Top institutions holding RAPP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 7.17M | 12.40% | +0.06% | Jun 2026 |
| TRV GP V, LLC | 6.28M | 10.86% | -11.98% | Jun 2026 |
| ARCH VENTURE CORP | 3.73M | 6.45% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.91M | 5.03% | -1.08% | Jun 2026 |
| BlackRock Inc | 2.70M | 4.67% | +7.73% | Jun 2026 |
| Cormorant Asset Management, LLC | 2.66M | 4.59% | -10.14% | Jun 2026 |
| Capital Research & Mgmt Co - Division 3 | 2.65M | 4.59% | -9.18% | Sep 2026 |
| Sofinnova Ventures | 1.90M | 3.29% | 0.00% | Jun 2026 |
| Johnson & Johnson | 1.78M | 3.08% | 0.00% | Jun 2026 |
| Polar Capital Holdings PLC | 1.61M | 2.78% | -2.07% | Jun 2026 |
| Baker Bros Advisors LP | 1.55M | 2.67% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.35M | 2.33% | +1.62% | Jun 2026 |
| TRV GP VI, LLC | 969K | 1.68% | 0.00% | Jun 2026 |
| State Street Corp | 819K | 1.42% | +7.79% | Jun 2026 |
| Geode Capital Management, LLC | 793K | 1.37% | +9.95% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 787K | 1.36% | -9.12% | Jun 2026 |
| Perceptive Advisors LLC | 773K | 1.34% | +14.75% | Jun 2026 |
| Vestal Point Capital LP | 730K | 1.26% | -49.17% | Jun 2026 |
| AllianceBernstein L.P. | 693K | 1.20% | -4.73% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 644K | 1.11% | -29.90% | Jun 2026 |
Rapport Therapeutics, Inc. Common Stock company profile
- Company name
- Rapport Therapeutics, Inc. Common Stock
- Ticker
- RAPP.US
- Exchange
- USA Stocks
- Listed since
- Jun 7, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 84
- Fiscal year end
- December
- Address
- 99 High Street, Boston, MA, United States, 02110
- Phone
- 857 321 8020
- Website
- rapportrx.com
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Rapport Therapeutics, Inc. Common Stock management
10- Dr. Steven M. Paul M.D.Founder & Independent Chairman · born 1951
- Mr. Abraham N. Ceesay M.B.A.CEO, President, Treasurer & Director · born 1978
- Mr. Troy A. IgnelziChief Financial Officer · born 1968
- Dr. Jeffrey Sevigny M.D.Chief Medical Officer · born 1969
- Dr. David Bredt M.D., Ph.D.Founder & Chief Scientific Officer · born 1965
- Ms. Cheryl GaultChief Operating Officer · born 1979
- Ms. Karina ChmielewskiChief Information Officer & Head of Operations
- Ms. Julie DiCarloHead of Communications & Investor Relations
- Ms. Kathleen A. WilkinsonChief People Officer · born 1972
- Mr. Swamy Yeleswaram Ph.D.Chief Development Officer · born 1963